Key Takeaways U.S. market traction, rising respiratory disease demand, and updated guidelines position the company for strong recurring revenue and margin expansion via Technegas adoption. Operational leverage from earlier investments and expanding Technegas indications drive volume growth, improved earnings, and higher annuity-like income streams.Read more
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribution of third-party products to the diagnostic imaging sector. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.
